PRDM9 and prostate carcinoma: Notably, the activity of NSD2 as a histone methyltransferase has been shown to be coordinately regulated by EZH251, a major component of the histone methyltransferase polycomb repressive complex 2 (PRC2), which is also dysregulated in prostate cancer.